Table 4.
Selected study of novel drugs currently under investigation in the treatment of relapsed/refractory PTCLs
*Response by central review.
†Interim analysis reported in abstract based on 30 patients; responses reported in abstract by investigator assessment.
‡Interim analysis.
§Responses described in table are for PTCL patients only.
